Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Sanofi’s…
Novartis has announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity ambitions as a focused medicines company in the coming decade.
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its anti-CD112R monoclonal antibody (TAB009/JS009) for the treatment of advanced solid tumors.
Bristol Myers Squibb (NYSE: BMY) has announced results from the Phase 3 VALOR-HCM study, which showed the addition of mavacamten, an investigational, first-in-class cardiac myosin inhibitor, significantly reduced the need for septal reduction therapy (SRT) in patients with severely symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM) who had been appropriate for SRT per the 2011 American College of Cardiology/American Heart Association (ACC/AHA) Guidelines at baseline.
Vivoryon Therapeutics N.V. has completed a private placement by way of accelerated bookbuilding, placing 2,000,000 registered shares at an offering price of EUR 10.50 per share.
Sanofi has announced that the French Autorité des marchés financiers (AMF) has approved the listing prospectus prepared by EUROAPI in connection with the intended listing of its shares on the regulated market of Euronext Paris.
Achieving classical herd immunity against SARS-CoV-2, the virus that causes COVID-19, may not be attainable, according to a new perspective published in The Journal of Infectious Diseases.
Vivoryon Therapeutics N.V., a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, has announced the launch of a private placement by way of an accelerated bookbuilding process to institutional investors offering up to 2,000,000 newly issued registered shares, representing up to approximately 10% of the company’s issued share capital.
Abzena Thrusday announced a new round of investment. Funding sources for the additional $65 million include majority-owner Welsh, Carson, Anderson & Stowe (WCAS), Biospring Partners, and other affiliated investors.
The Solvay Brussels School of Economics and Management in collaboration with the ULB research institute I3h has launched a new Advanced Master in Biotech & MedTech Ventures. The programme addresses the thriving Belgian and European life sciences’ need for young entrepreneurial talent capable of taking on (C-level) management positions in early-stage Biotech and MedTech companies.